For investors only

All about the drug candidate arfolitixorin
and related information

STRATEGY

Isofol has carried out a comprehensive analysis of the available data for arfolitixorin, both from the AGENT study and from other clinical and preclinical studies. Based on current knowledge, the company deems it possible to further improve the efficacy of the drug candidate by using an optimized dosage regimen. The company has therefore decided to carry out a clinical Phase I/II study of arfolitixorin in combination with 5-FU-based cytostatic therapies in treatment-naive mCRC patients. The study aims to generate efficacy and safety data ahead of the continued development and commercialization of the product. 

Generate new efficacy data

After analyses indicated that the AGENT study did not reach its goal due to an insufficient dose and inappropriate administration, Isofol has decided to carry out a clinical Phase I/II study of arfolitixorin in partnership with a leading academic research center with a new dosage regimen. Intense work to define the exact study design is ongoing, with the goal of initiating the study before the end of 2024 using existing funds.

Taking advantage of strong partnerships

The company will continue its close cooperation with its current strategic partners, particularly with Merck & Cie as a strategic development and production partner and with Solasia when it comes to the commercialization of the drug candidate in Japan.

Good cost control

Financial stability is another focus area and good cost control helps to maximize the company’s longevity. Resources are invested in value-creating activities such as the clinical study and other costs are minimized. The company’s partnerships with consultants and suppliers provide an adaptable and flexible cost base.

Financial stability is another focus area and good cost control helps to maximize the company’s longevity. Resources are invested in value-creating activities such as the clinical study and other costs are minimized. The company’s partnerships with consultants and suppliers provide an adaptable and flexible cost base.

Last updated 05-20-2024